OUR RESEARCH
Genetic analysis of the OHTS cohort
The Ocular Hypertension Treatment Study (OHTS) was a landmark clinical trial that demonstrated the efficacy of lowering eye pressure in preventing or delaying the onset of glaucoma. Our primary goals are:
​
-
Create glaucoma risk calculators with genetic factors
-
Characterize glaucoma risk loci
-
Determine the specific genetic variations that confer risk for glaucoma
-
Determine the effect of these variations on gene expression
-
-
We have shown how variants in the TMCO1 gene increase the probability for glaucoma in OHTS participants. Read more about it here.​
![](https://static.wixstatic.com/media/f9664d_3ff72c5c7a79497bab1a0ce811db7790~mv2.png/v1/fill/w_333,h_308,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/f9664d_3ff72c5c7a79497bab1a0ce811db7790~mv2.png)
Stem Cell Approaches to Glaucoma Research
We have collected cells from 1000+ patients with glaucoma for research in collaboration with our colleague Dr. Budd Tucker and his stem cell laboratory.
​
-
We have obtained cells from patients with known molecular causes of their glaucoma
-
Myocilin (MYOC) mutations (Gly367Arg, Gln368Ter, Tyr437His)
-
TANK-binding kinase 1 (TBK1) gene duplication
-
TANK-binding kinase 1 (TBK1) gene triplication
-
Optineurin (OPTN) mutations (Glu50Lys)
-
-
Isogenic cell lines are in production to serve as controls
-
Disease modeling experiments are underway
-
We have established that a TBK1 gene duplication stimulates increased autophagy, which may be a key step in glaucoma associated with this mutation. Read more about it here.
![nihms583013f5.jpg](https://static.wixstatic.com/media/f9664d_39f969d65a0b42a68266d9951d99d39f~mv2.jpg/v1/fill/w_223,h_148,al_c,q_80,usm_0.66_1.00_0.01,enc_avif,quality_auto/f9664d_39f969d65a0b42a68266d9951d99d39f~mv2.jpg)
MYOC Glaucoma
We discovered the first glaucoma gene, myocilin (MYOC). MYOC mutations cause 3-4% of glaucoma worldwide and are the most common known cause of glaucoma.
​
-
We identified the first glaucoma-causing mutations in myocilin. Read more here.
-
We described the clinical features of glaucoma associated with myocilin mutations. Read more here.
-
We discovered how myocilin mutations cause glaucoma. Read more here.
-
We conducted the first histological analysis of a myocilin glaucoma patient's eye. Read more here.
-
We report CRISPR/Cas9 genome editing of myocilin mutations in mice. Read more here.
-
Access all of our myocilin research articles here.
-
We offer non-profit myocilin testing in our CLIA-certified diagnostic laboratory - The Carver Labs.
![](https://static.wixstatic.com/media/f9664d_e9af4636937a4655b683189ca129f152~mv2.png/v1/fill/w_222,h_204,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/f9664d_e9af4636937a4655b683189ca129f152~mv2.png)
TBK1 Glaucoma
We discovered that TBK1 gene duplications and triplications are associated with glaucoma that occurs at average or low eye pressures.
​
-
We identified the first glaucoma-causing mutations in TBK1. Read more here.
-
We identified the long-term clinical course of glaucoma associated with TBK1 mutations. Read more here.
-
We used genome sequencing to map the TBK1 gene duplications in several patients. Read more here.
-
We created transgenic mice that have glaucoma due to TBK1 gene duplications Read more here.
-
We grew retinal ganglion cells (optic nerve tissue) from a TBK1 glaucoma patient's skin. Read more here.
-
Access all of our TBK1 research articles here.
![](https://static.wixstatic.com/media/f9664d_7c66c782f42442e5bfabdbc4acbeb176~mv2.png/v1/crop/x_0,y_3,w_657,h_617/fill/w_223,h_209,al_c,q_85,usm_0.66_1.00_0.01,enc_avif,quality_auto/f9664d_7c66c782f42442e5bfabdbc4acbeb176~mv2.png)